Evidence map›Paper›PMID 33484418›Full record

ArticleInternational journal of hematology2021

Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.

Tadashi Kumamoto, Hiroaki Goto, Chitose Ogawa, Toshinori Hori, Takao Deguchi, Takuya Araki, Akiko M Saito, Atsushi Manabe, Keizo Horibe, Hidemi Toyoda

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Tadashi KumamotoDepartment of Pediatric Oncology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo, 104‑0045, Japan. tkumamot@ncc.go.jp.
Hiroaki GotoDepartment of Hematology and Oncology, Children's Cancer Center, Kanagawa Children's Medical Center, Yokohama, Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo, 104‑0045, Japan.
Toshinori HoriDepartment of Pediatrics, Aich Medical University Hospital, Nagoya, Japan.
Takao DeguchiDivision of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Takuya ArakiDepartment of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Akiko M SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Atsushi ManabeDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Hidemi ToyodaDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33484418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.